Journal article

A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors

Hui K Gan, Mark A Rosenthal, Anthony Dowling, Renate Kalnins, Elizabeth Algar, Nicholas Wong, Angela Benson, Anne-Marie Woods, Lawrence Cher

NEURO-ONCOLOGY | OXFORD UNIV PRESS INC | Published : 2010

Abstract

Glial tumors with oligodendroglial components are considered chemo-responsive. Forty newly diagnosed patients (11 anaplastic oligodendrogliomas [OD] and 29 anaplastic oligoastrocytomas [OA]) were enrolled into this multicenter, open-label, single-arm Phase II trial of first-line temozolomide (200 mg/m(2) on days 1-5 every 4 weeks for 6 cycles). The primary endpoint was 6-month progression-free survival (PFS) with response rate (RR), median PFS, and median overall survival (OS) as secondary endpoints. Of 39 evaluable patients at the 6-month time point (median follow-up, 34 months), 6-month PFS was 77% (95% confidence interval [CI], 74.5%-79.3%). There were 15 complete responses (CRs, 38%), 6 ..

View full abstract